Last reviewed · How we verify

Pheochromocytoma — Treatment Landscape & Competitive Intelligence

Pheochromocytoma (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Pheochromocytoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Demser metirosine Aton Pharma Vpna Catecholamine Synthesis Inhibitor [EPC] Tyrosine 3-monooxygenase 1979-01-01
Azedra Azedra David Bushnell Sodium-dependent noradrenaline transporter

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Aton Pharma Vpna · 1 drug in Pheochromocytoma
  2. David Bushnell · 1 drug in Pheochromocytoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Pheochromocytoma:

Cite this brief

Drug Landscape (2026). Pheochromocytoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pheochromocytoma. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing